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June 2012 to March 2014. SAD patients who remain symp-
tomatic following antidepressant treatment were recruited, 
and a total sample size of 42 was set based on pilot results. 
 Results: Patients were randomly allocated to CBT + UC (n = 
21) or UC alone (n = 21). After 16 weeks, adjusted mean reduc-
tion in the Liebowitz Social Anxiety Scale from baseline for 
CBT + UC and UC alone was  − 40.87 and 0.68, respectively; the 
between-group difference was  − 41.55 ( − 53.68 to  − 29.42,
p < 0.0001). Response rates were 85.7 and 10.0% for CBT + UC 
and UC alone, respectively (p < 0.0001). The corresponding 
remission rates were 47.6 and 0.0%, respectively (p = 0.0005). 
Significant differences were also found in favor of CBT + UC 
for social anxiety symptoms, depressive symptoms, and func-
tional impairment.  Conclusions: Our results suggest that in 
SAD patients who have been ineffectively treated with anti-
depressants, CBT is an effective treatment adjunct to UC over 
16 weeks in reducing social anxiety and related symptoms. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: Although antidepressants are still a commonly 
used treatment for social anxiety disorder (SAD), a significant 
proportion of patients fail to remit following antidepres-
sants. However, no standard approach has been established 
for managing such patients. This study aimed to examine the 
effectiveness of cognitive behavioral therapy (CBT) as an ad-
junct to usual care (UC) compared with UC alone in SAD pa-
tients who remain symptomatic following antidepressant 
treatment.  Methods: This was a prospective randomized 
open-blinded end-point study with two parallel groups
(CBT + UC, and UC alone, both for 16 weeks) conducted from 
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 Introduction 
 Social anxiety disorder (SAD) is a highly prevalent 
psychiatric disorder associated with considerable voca-
tional and psychosocial handicaps and an increased risk 
for complications such as depression and suicidality  [1] . 
SAD has a low natural recovery rate (only 37% over 12 
years) compared with major depressive disorder and oth-
er anxiety disorders  [2] . Thus, effective and accessible 
treatments for SAD are in high demand by both patients 
and health care organizations.
 The treatment options for SAD are psychotherapy and 
pharmacotherapy. With regard to pharmacotherapy, an-
tidepressants have been recommended as the first-line 
treatment for SAD  [3–5] . However, a significant propor-
tion of patients with SAD fail to respond to antidepres-
sants (40–60% are nonresponders over 12–20 weeks of 
treatment)  [6, 7] . Although the inappropriateness of an-
tidepressants due to their low response rates and adverse 
effects should be discussed, antidepressants are still com-
monly used as a first-choice treatment for SAD  [8] . Some 
reviews have advocated augmentation with other phar-
macological agents or switching to another antidepres-
sant; however, the evidence for such treatment is limited 
 [5] . While some reports have been published on the ef-
fectiveness of pharmacotherapy combined with cognitive 
behavioral therapy (CBT)  [9] , no data are available on the 
effectiveness of a combined therapy targeting patients 
who remain symptomatic despite adequate antidepres-
sant trials.
 Clearly, much more work needs to be done to garner 
evidence and then establish a treatment guideline for pa-
tients with SAD who have been ineffectively treated with 
antidepressants. In the depression literature, a large-scale 
randomized controlled trial has recently demonstrated 
the effectiveness of augmenting pharmacotherapy with 
CBT in treatment-resistant depression  [10] , marking a 
milestone in the use of CBT for managing patients who 
remain symptomatic despite adequate antidepressants; 
however, a systematic review has revealed no such studies 
in the literature on SAD  [11] . Some studies of individual 
CBT (e.g. Clark et al.  [12] in 2006) and our preliminary 
study  [13] have included a subset of patients who have 
been ineffectively treated with antidepressants. These 
studies have reported a subanalysis, which showed that 
they do not differ in their response to individual CBT. 
These findings suggest that CBT for SAD is an effective 
treatment option, even in patients who failed to remit af-
ter receiving antidepressants; however, the sample size 
for this comparison was very small in the subanalysis, so 
the absence of a significant difference is not informative. 
What is really needed is an effectiveness trial of CBT as a 
next-step treatment in this population.
 Here, we conducted a randomized controlled trial to 
examine the effectiveness of CBT as an adjunct to usual 
care (UC) compared with that of UC alone, specifically 
targeting cases who remain symptomatic despite treat-
ment with selective serotonin reuptake inhibitors
(SSRIs). We hypothesized that among SAD patients who 
remain symptomatic following antidepressants, the aug-
mentation with CBT would be superior to UC alone in 
reducing the severity of social anxiety and depressive 
symptoms and improving functioning or quality of life.
 Methods 
 Study Design and Participants 
 The study protocol has been published elsewhere  [14] and, 
therefore, it is only summarized here. This was a prospective ran-
domized open-blinded end-point single-center trial conducted at 
the psychiatric outpatient section of Chiba University Hospital be-
tween June 2012 and March 2014. Participants were recruited 
through posters and leaflets placed at medical institutions in Chiba 
Prefecture and through web-based and newspaper advertisements. 
The primary inclusion criterion was patients with SAD who re-
main symptomatic despite treatment with SSRI. Both arms of the 
trial received active interventions for 16 weeks: one group received 
CBT combined with UC (CBT + UC group) and another received 
UC alone (UC group). UC included pharmacotherapy provided by 
a primary psychiatrist.
 Prospective patients were included according to the following 
criteria: a primary diagnosis of SAD according to the DSM-IV cri-
teria (no restriction on subtype); age 18–65 years; symptomatic 
status of at least a moderate level of severity (Liebowitz Social Anx-
iety Scale, LSAS score  ≥ 50  [15, 16] ), and having received adequate 
treatment with at least one SSRI at maximum-dose treatment for 
at least 12 weeks, or intolerance to at least one SSRI. Comorbid 
diagnoses were permitted if they were clearly secondary. Exclusion 
criteria included psychosis, pervasive developmental disorder/
mental retardation, autism spectrum disorders, current high risk 
of suicide, substance abuse/dependence within the 6 months prior 
to enrolment, antisocial personality disorder, any unstable medical 
condition, pregnancy, or lactation. Patients were also excluded if 
they reported ‘much’ to ‘very much’ improvement in the Clinical 
Global Impression (CGI) scale  [17] following any type of treat-
ment (e.g. medication, psychotherapy, or both) in the 12 weeks 
prior to the study.
 Written informed consent was obtained from all patients after 
the procedures had been fully explained. Ethical approval was ob-
tained from the Institutional Review Board of Chiba University 
Hospital (G23075), and the trial was registered as UMIN000007552.
 Randomization and Masking 
 At the end of baseline assessment, eligible patients were ran-
domly assigned to the CBT + UC or UC group in a 1: 1 ratio using 
the minimization method with biased-coin assignment balancing 
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on primary outcome score (LSAS 50–70 or  ≥ 70)  [15] , sex, and 
presence or absence of current treatment with SSRIs. For details of 
the study management, see online supplementary appendix 1 (see 
www.karger.com/doi/10.1159/000444221 for all online suppl. ma-
terial).
 To ensure blinding, the independent assessors had no other 
contact with the patients. Success of blinding was assessed at weeks 
8 and 16 based on Bang’s method  [18] by asking ‘Which type of 
treatment do you think the patient received during the trial?’ with 
possible responses being ‘CBT + UC’, ‘UC alone’, or ‘don’t know’.
 Procedures 
 Primary psychiatrists referred patients to the trial, but contin-
ued to provide UC to the patients in both groups. They had no 
restrictions placed on UC available to them, and medication 
change was allowed. However, the initiation of a strictly structured 
CBT program was banned in the UC group in order to properly 
assess the effectiveness of CBT. All treatment changes, with the 
reasons for these changes, were recorded throughout the study.
 Our CBT program was based on the model of Clark and Wells 
 [19] and conducted over 16 weekly individual sessions. Most ses-
sions lasted for 50 min; however, the treatment manual allowed 
therapists to extend up to 6 sessions to a maximum of 90 min each 
to facilitate behavioral experiments. The main treatment steps are 
presented in online supplementary appendix 2.
 CBT Therapist and Quality Control 
 CBT was delivered by seven therapists experienced in the use 
of CBT for patients with SAD (four clinical psychologists, one psy-
chiatrist, one nurse, and one psychiatric social worker). Four of the 
seven therapists had experience providing CBT in our preliminary 
study  [13] . All therapists had completed a CBT training course 
(Chiba Improving Access to Psychological Therapies project: Chi-
ba-IAPT)  [20] and received an additional 14-hour special work-
shop about CBT for SAD. Online supplementary appendix 3 pro-
vides more details of therapist training. Five of the seven therapists 
were female, aged 36.5 years (standard deviation, SD = 5.1), with 
6.7 years of clinical experience (SD = 3.9) and 3.5 years of experi-
ence as a CBT therapist (SD = 2.7) at the beginning of the study. 
To assist with session planning, all therapists attended weekly 
group and individual supervision sessions with a senior supervisor 
(E.S.). Therapist competence was assessed with a random sample 
of recordings by raters from the Chiba-IAPT with the Revised 
Cognitive Therapy Scale (CTS-R)  [21] .
 Outcomes 
 Assessments were conducted at weeks 0 (baseline), 8 (mid-
intervention), and 16 (postintervention). The primary outcome 
was independent assessor-determined symptoms of social anxi-
ety, as measured by the total LSAS score  [15] . Treatment response 
was defined as a 31% or greater reduction in the total LSAS score, 
and remission was defined as having a final LSAS score of  ≤ 36 and 
no longer meeting the diagnostic criteria for SAD (DSM-IV-TR). 
Secondary outcomes were self-reported using the Social Phobia 
and Anxiety Inventory (SPAI)  [22] , the Beck Depression Inven-
tory-II (BDI-II)  [23] , the Sheehan Disability Scale (SDS)  [24] , the 
WHO Quality of Life-26 item version (WHOQOL-26)  [25] , and 
the EuroQol-5 Dimensions (EQ-5D)  [26] . The CGI-Severity/Im-
provement (CGI-S/I)  [17] was evaluated by independent asses-
sors.
 Statistical Analysis 
 Sample size was based on our pilot results, which indicated an 
estimated group difference in LSAS scores of 30 points (SD = 30), 
requiring 18 patients per arm to provide >80% power to detect a 
difference between the two groups over 16 weeks, using a two-
sided, two-sample t test at a 5% significance level. Thus, allowing 
for a 20% dropout rate, 21 patients were required per group.
 Statistical analysis and reporting were conducted in accordance 
with Consolidated Standards of Reporting Trials (CONSORT) 
guidelines, with the primary analyses based on the intent-to-treat 
principle without inputting missing observations. Descriptive sta-
tistics of patient characteristics were provided using frequencies 
and proportions for categorical data and means and SD for con-
tinuous variables. The baseline variables were compared using 
Fisher’s exact test for categorical outcomes and unpaired t tests for 
continuous variables, as appropriate.
 The primary outcome of change in LSAS from baseline at week 
16 was analyzed by analysis of covariance (ANCOVA), with treat-
ment as the fixed effect and the baseline LSAS score (LSAS 50–70 
or  ≥ 70), sex, and current treatment with SSRIs as covariates. Ad-
justed mean differences are provided with 95% confidence inter-
vals (CIs).
 For sensitivity analysis, linear mixed-effects models were used 
for dimensional outcomes to determine the means at each assess-
ment point (weeks 8 and 16) and to test the between-group differ-
ences at week 16. Time and treatment were included as fixed ef-
fects, and intercept and linear slope terms were included as ran-
dom effects. An unstructured covariance was used to account for 
within-subject correlation over time. Secondary analyses were per-
formed similarly to the primary analysis. The success of blinding 
was measured using Bang’s blinding index in a 2 × 5 format  [18] .
 All comparisons were planned. Two-sided p values <0.05 were 
considered statistically significant. Statistical analyses were per-
formed using SAS software version 9.4 (SAS Institute, Cary, N.C., 
USA) and Stata/IC 11.2 (StataCorp, College Station, Tex., USA) 
with the ‘blinding’ module written by Jiefeng Chan of the Texas 
A&M University.
 Results 
 Recruitment 
 Figure 1 shows the patient flow. Of the 74 patients who 
applied to participate through our website, 50 attended 
the face-to-face baseline assessment; 42 were enrolled
the study. We randomly assigned 21 patients each to the 
CBT + UC and UC groups. One patient dropped out from 
the study in the UC group before the assessment at week 
8 because the severity of depression markedly increased. 
The outcome data for this dropout was included in the 
intent-to-treat analysis by multiple imputation (data 
analysis was based on all patients).
 Demographics and Clinical Characteristics 
 Table  1 summarizes the baseline demographic and 
clinical characteristics, demonstrating no significant dif-
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ferences between the study groups. With regard to clini-
cal characteristics, 37 patients (88.1%) had a generalized 
subtype, 14 (33.3%) had an additional axis I diagnosis, 
and the mean total LSAS score at baseline was 82.3 (SD = 
18.8).
 Treatment 
 No significant differences were noted between the 
groups in antidepressant (imipramine-equivalent) dose 
or anxiolytic (diazepam-equivalent) dose throughout the 
study (see online suppl. table 1 for more details). Two pa-
tients started another antidepressant during the trial (1 in 
each group). In the CBT + UC group, the patient restart-
ed escitalopram. In the UC group, the patient started
trazodone. Other antidepressant changes are as follows: 
increased: CBT + UC (n = 2), UC (n = 1); decreased:
CBT + UC (n = 1), UC (n = 1); stopped: CBT + UC (n = 
1), UC (n = 2), and other (stopped one of two antidepres-
sants, and increased the other): CBT + UC (n = 1). Online 
supplementary table 2 describes more details.
 With regard to CBT, on average, 15.8 sessions (SD = 
0.6) were completed over 19.7 weeks (SD = 4.2). The to-
tal mean CTS-R rating was 43.4 (SD = 1.4) for 21 (6.3%) 
randomly selected sessions from all 331 sessions (1 ses-
sion from each case), which was over the competence 
threshold (>36) expected in UK-CBT training programs 
 [21] .
 Primary Outcomes 
 Changes in LSAS scores are shown in  figure 2 . At 
week 8, mean reductions in LSAS from baseline were 
 − 19.67 (95% CI:  − 27.08 to  − 12.26) and  − 0.95 (95% CI: 
42 were included in 
random assignment
50 attended face-to-face 
baseline assessment
68 received mail or
telephone screening
13 did not meet inclusion criteria:
  2 were excluded because SAD was not the 
  primary diagnosis
  8 did not meet the criteria of SSRI resistance
  3 met the exclusion criteria of diagnosis
  5 declined to participate
18 were excluded:
6 were excluded because SAD was not the 
primary diagnosis
2 did not meet the criteria of SSRI resistance
8 were excluded for not meeting inclusion criteria:
6 lost contact
74 applied for the study
21 were allocated to CBT + UC 21 were allocated to UC alone
21 completed the study 20 completed the study
21 were included in the
intent-to-treat analysis
21 were included in the
intent-to-treat analysis
1 did not complete (drastic increase
   in severity of depressive symptoms)
 Fig. 1. CONSORT flow diagram for the trial. 
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 − 8.20 to 6.30) for the CBT + UC and UC groups, respec-
tively. As with primary analysis, adjusted mean reduc-
tions were  − 40.87 (95% CI:  − 50.05 to  − 31.68) and 0.68 
(95% CI:  − 8.49 to 9.85), respectively. The group differ-
ence was  − 41.55 (95% CI:  − 53.68 to  − 29.42, p < 0.0001). 
Combination therapy (CBT + UC) was therefore supe-
rior to UC alone. According to the primary outcome 
measure (LSAS), a significantly greater proportion of 
patients in the CBT + UC group achieved response 
(85.7%) and remission (47.6%) after intervention com-
pared with the UC group (10% and 0%, respectively; p < 
0.0001 and p = 0.0005).
 Secondary Outcomes 
 Results for secondary outcome measures are presented 
in  table 2 . At week 8, compared with the UC group, sig-
nificant improvements were observed in the CBT + UC 
group in the SPAI, CGI-S, and CGI-I scores (all p < 0.05). 
At week 16, compared with the UC group, significant im-
provements were observed in all secondary outcomes in 
the CBT + UC group (all p < 0.05). This result shows that, 
compared with the UC group, measures of social phobia, 
depression, and functioning or quality of life improved by 
week 16 in the CBT + UC group.
 Blinding 
 At week 8, blinding indices in the CBT + UC and UC 
groups were  − 0.01 (95% CI:  − 0.13 to 0.15) and 0.11 (95% 
CI:  − 0.04 to 0.26), respectively. At week 16, the respective 
values were 0.19 (95% CI: 0.11 to 0.37) and  − 0.25 (95% 
CI:  − 0.20 to 0.15). These results suggested that blinding 
was unsuccessful in the CBT + UC group at the postin-
tervention assessment (p = 0.04; see online suppl. tables 4 
and 5 for more details).
 Table 1.  Baseline characteristics
Variable CBT + UC 
(n = 21)
UC 
(n = 21)
Male sex 13 (61.9) 12 (57.1)
Age, years 32.5 ± 8.2 31.6 ± 9.2
Length of education, years 14.8 ± 1.7 14.1 ± 1.7
Marital status (married or living as married) 4 (19.1) 3 (14.3)
Employment status (in paid employment, full or part-time) 7 (33.3) 8 (38.1)
Financial status (no financial difficulty) 8 (38.1) 10 (47.6)
Subtype of SAD (generalized) 19 (90.5) 18 (85.7)
Age at onset of SAD, years 18.1 ± 8.0 19.0 ± 6.5
Severity of SAD (LSAS total score) 82.2 ± 20.4 82.4 ± 17.5
Additional axis I diagnosis
No comorbid condition (SAD only) 12 (57.1) 16 (76.2)
Major depressive disorder 5 (23.8) 4 (19.1)
Others 4 (19.1) 1 (4.8)
Number of past SSRI trials 1.7 ± 0.8 1.5 ± 0.7
Baseline antidepressant (imipramine equivalent dose), mg/day 70.5 ± 62.2 84.5 ± 98.9
Baseline anxiolytics (diazepam equivalent dose), mg/day 3.5 ± 4.3 6.7 ± 10.6
 Values are n (%) or means ± SD, as appropriate. There were no group differences on any variables. 
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 Fig. 2. Changes in primary outcome (LSAS; see online suppl. ta-
ble 3 for raw data). Bars indicate 95% CI. 
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 Discussion 
 This is the first randomized controlled trial that has 
examined the effectiveness of CBT as a next-step treat-
ment for patients with SAD who remain symptomatic de-
spite SSRI treatment. Over 16 weeks, CBT was effective as 
an adjunct to UC in reducing the severity of social anxiety 
symptoms, depressive symptoms, and functional disabil-
ity.
 Baseline clinical characteristics of our recruited pa-
tients in Japan were different from those of epidemiolog-
ical data in Western countries (e.g. low comorbid depres-
sion, a high number of single and unemployed partici-
pants, and a high rate of financial problems). It is difficult 
to explain the reason for this, though a possible factor is 
culturally different backgrounds  [27, 28] . For example, 
epidemiological data in the USA revealed that 34% of 
SAD patients have comorbidity of depression  [28] , where-
as in Japanese clinical settings, only 21% of patients have 
comorbid depression (25.7% in severe cases, LSAS >90) 
 [29] . Therefore, our study population seems to reflect 
routine clinical practice in Japan; future study should rep-
licate our findings with larger samples.
 A report comparing CBT + UC with UC alone for the 
management of treatment-refractory depression report-
ed that 15% of patients met the remission criteria in the 
 Table 2.  Changes in secondary outcomes
Measures and time points CBT + UC (n = 21) UC (n = 21) p value
mean ± SD 95% CI mean ± SD 95% CI
SPAI (range: 0 – 144)
Week 0 110.0 ± 24.6 99.4 – 120.5 115.1 ± 22.0 105.7 – 124.6 0.399
Week 8 97.7 ± 24.1 87.4 – 108.0 114.4 ± 22.7 104.6 – 124.1 0.038*
Week 16 81.8 ± 31.6 68.3 – 95.3 115.4 ± 23.0 105.5 – 125.2 0.0011**
BDI-II (range: 0 – 63)
Week 0 22.3 ± 11.6 17.4 – 27.3 18.4 ± 10.5 13.9 – 22.9 0.232
Week 8 14.8 ± 7.7 11.5 – 18.1 18.4 ± 11.5 13.4 – 23.3 0.447
Week 16 10.9 ± 10.4 6.5 – 15.3 19.4 ± 11.2 14.6 – 24.1 0.0094**
SDS (range: 0 – 30)
Week 0 16.6 ± 5.8 14.1 – 19.0 14.7 ± 5.5 12.3 – 17.1 0.313
Week 8 11.4 ± 5.9 8.9 – 14.0 14.4 ± 6.8 11.4 – 17.3 0.143
Week 16 10.4 ± 7.5 7.2 – 13.6 14.9 ± 6.1 12.2 – 17.6 0.022*
WHOQOL-26 (range: 26 – 130)
Week 0 68.3 ± 13.7 62.5 – 74.2 71.8 ± 12.0 66.5 – 77.1 0.339
Week 8 72.8 ± 10.9 68.1 – 77.5 73.2 ± 12.5 67.7 – 78.6 0.906
Week 16 79.9 ± 18.1 72.1 – 87.6 71.7 ± 9.4 67.5 – 75.8 0.022*
EQ-5D (range: −0.111 to 1.000)
Week 0 0.7 ± 0.1 0.6 – 0.7 0.7 ± 0.1 0.7 – 0.8 0.129
Week 8 0.7 ± 0.2 0.6 – 0.8 0.7 ± 0.1 0.7 – 0.8 0.989
Week 16 0.8 ± 0.2 0.7 – 0.9 0.7 ± 0.2 0.7 – 0.8 0.0086**
CGI-S (range: 0 – 7)
Week 0 5.1 ± 1.0 4.7 – 5.5 5.0 ± 0.7 4.7 – 5.2 0.447
Week 8 4.0 ± 1.1 3.5 – 4.4 4.6 ± 0.9 4.2 – 5.0 0.028*
Week 16 2.6 ± 1.3 2.0 – 3.1 4.8 ± 1.1 4.3 – 5.2       <0.0001**
CGI-I (range: 0 – 7)a
Week 8 3.1 ± 0.8 2.7 – 3.4 3.9 ± 0.3 3.8 – 4.0       <0.0001**
Week 16 2.1 ± 1.1 1.6 – 2.6 4.1 ± 0.8 3.7 – 4.4       < 0.0001**
Intenti on-to-treat sample. Measures: higher scores on the WHOQOL-26 and EQ-5D indicate better QOL, 
and those on the other measurements indicate greater pathology or severity. * p < 0.05, ** p < 0.01.
a Compared with baseline assessment (week 0).
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UC group compared with 28% in the CBT + UC group at 
the 6-month follow-up  [10] . In our study, none of the pa-
tients receiving UC alone met the remission criteria at 
week 16, while 47.6% met the criteria in the CBT + UC 
group. This indicates that simple continuation of UC on 
the basis of the judgment of the primary psychiatrists was 
largely ineffective for our population of patients with 
SAD and that clinicians should consider providing CBT 
or referring patients to a CBT therapist if SSRI treatment 
is not sufficiently effective.
 Obviously, a standardized operational definition for 
describing the phenomenon of ‘patients who remain 
symptomatic following antidepressant treatment’ in SAD 
is necessary to improve the ecological validity of future 
results in this field. It should be discussed in order to de-
fine antidepressant treatment-resistant SAD in terms of 
the differentiation between nonresponse, loss of efficacy, 
and resistance  [8] . There is a wide variety of terminology 
(and its use) for this phenomenon, with the use of such 
different words as ‘refractory’, ‘nonresponsive’, ‘incom-
pletely responsive’, and ‘nonremitter’  [11] . Therefore, we 
needed to describe the phenomenon of ‘patients who re-
main symptomatic following antidepressant treatment’ 
in this study because no agreed-upon definition existed. 
This was particularly relevant given that our sample had 
more severe symptoms (mean LSAS >80) than those in 
most previous trials  [9, 30, 31] . Some drug-switching tri-
als have targeted more restricted SSRI nonresponders, 
but patients in those studies had less severe SAD symp-
toms (mean LSAS <80) than those in our study  [16, 32] . 
We therefore think that our results are more representa-
tive of patients with severe SAD symptoms that have been 
insufficiently treated with antidepressant treatment. 
 Several trials have assessed medication augmentation/
switching strategies for SAD patients who have not been 
effectively treated with antidepressants. For example, van 
Ameringen et al.  [33] evaluated the efficacy of buspirone 
augmentation of SSRIs for SAD patients, obtaining only 
a partial response to an adequate SSRI trial in a small sam-
ple (n = 10). They reported that 7 patients (70%) achieved 
‘responder’ status (‘very’ or ‘very much’ improved in the 
CGI-I) over the 8-week treatment. Similarly, Pallanti and 
Quercioli  [32] investigated the efficacy of escitalopram in 
29 patients with SAD who did not respond to an adequate 
trial of paroxetine. After treatment for 12 weeks, 48.3% of 
their patients were considered responders (‘much’ or 
‘very much’ improved in CGI-I, and LSAS reduction of 
>35% compared with baseline). Only one randomized 
controlled trial was identified  [16] . In this trial, patients 
with SAD who were still symptomatic after sertraline 
treatment for 10 weeks received either add-on clonaze-
pam, add-on placebo, or a switch to venlafaxine. After 
further 12 weeks of treatment, 27% of the patients receiv-
ing sertraline and clonazepam achieved remission (LSAS 
 ≤ 30). In contrast, 17% achieved remission with sertraline 
plus placebo and 19% achieved remission with a switch to 
venlafaxine. However, none of these differences reached 
statistical significance. Our result that 85.7 and 40% of 
patients in our study responded to treatment and achieved 
remission after adjunctive CBT, respectively, was there-
fore a remarkable finding. However, accurate assessment 
of the effectiveness of next-step treatment options has 
been precluded by diverse definitions of resistance and 
outcome measures. Therefore, further controlled trials 
should compare these treatment options for treatment-
resistant SAD.
 Individual CBT led to considerable improvements in 
our population; however, CBT therapists had limited ex-
perience compared with those in previous studies  [34–
36] . We should also consider the results of the Cognitive 
Therapy Competence Scale (CTCS) against other studies, 
given that evidence suggests that competence predicts 
outcome in CBT for SAD  [37] . Although we did not eval-
uate the CTCS, when we calculated the pre-post effect size 
of the CBT arm by the same formula [(M pre-CBT – 
M post-CBT )/SD pooled ] using raw data from each study, our 
effect size of 2.00 for the LSAS was comparable to those 
in previous studies on individual-based CBT using the 
model of Clark and Wells  [19] (1.22–2.17)  [12, 30, 31, 35] . 
We should also take into consideration the time of each 
session across different studies. There are now seven pub-
lished randomized controlled trials of individual CBT 
based on the model of Clark and Wells  [19] , and the ab-
solute magnitude of the within-treatment change in so-
cial anxiety varies as a function of session duration. Trials 
which used longer sessions (up to 90 min) and involved 
an extensive number of behavioral experiments obtained 
improvements on the LSAS of almost 45 points  [12, 30] . 
By contrast, trials that only used sessions of 50 min and 
appear to have involved very few behavioral experiments 
reported improvements on the LSAS of only 30 points 
 [31, 36] . Although our protocol involved up to 16 weekly 
sessions, most of which lasted 50 min, and up to 6 sessions 
(minimum 3 sessions) lasting 90 min to facilitate behav-
ioral experiments, our observed improvements (40 
points) after receiving CBT are closer to the trials with 
longer sessions.
 Our individual CBT achieved a large treatment effect 
despite having CBT therapists with limited experience 
and targeting severe cases; four possible reasons may ac-
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count for this. First, our CBT therapists received suffi-
cient training before the trial (see online suppl. appendix 
3 and our published paper  [20] for more details). All of 
the therapists had a structured CBT training experience 
to provide high-intensity therapy as a Chiba-IAPT 
trainee (more than 400 h over 2 years, similar to UK-
IAPT). In addition to this basic training, they received 
an additional 14-hour special workshop about CBT for 
SAD. Second, there are possible nontreatment-specific 
effects. Patients’ preferences, motivation, and patient-
doctor interaction are examples of what may affect treat-
ment outcome in therapeutic trials  [38, 39] . In Japan, the 
effectiveness of CBT has recently become known, not 
only among professionals but also in the general public; 
however, there are few competent CBT therapists, and 
patients’ access to CBT is extremely limited  [40] . Thus, 
patients who received CBT may have had high expecta-
tions, preferences, motivation, and allegiance to CBT 
during the trial. Third, our sample size was relatively 
small. A recent meta-epidemiological study found that 
small-to-moderately sized trials had significantly larger 
estimates of treatment effects than large-sized trials 
(>1,000 patients)  [41] . Finally, high baseline severity on 
primary outcome might contribute to a larger treatment 
effect.
 Assessor blinding was broken in the CBT + UC group 
at the end of the trial, mainly because LSAS showed con-
siderable improvement only in the group receiving ad-
junctive CBT. At week 16, the assessors correctly guessed 
that patients were receiving CBT + UC in 13 cases (61.9%), 
giving the reasons ‘intuition’ (n = 7), ‘LSAS test result’
(n = 5), and ‘informed by the patient’ (n = 1). Thus, most 
correct guesses were determined by intuition or after rat-
ing the LSAS score, suggesting that unblinding had a min-
imal impact on primary outcome ratings.
 This study has several limitations. First, most patients 
were recruited from outside our hospital, but CBT was 
delivered in our single-center facility; the quality of CBT 
therapists was somewhat different from that observed in 
routine clinical practice. Second, we did not set psycho-
logical placebo-controlled conditions; it is unclear wheth-
er factors unrelated to the treatment-specific effects might 
have contributed to the large effects of the psychological 
treatment. Third, the lack of follow-up data limits the 
generalizability of our conclusions to longer-term out-
comes. Studies using longer-term CBT may affect relapse 
rates and cost-effectiveness, and data of long-term effec-
tiveness will be analyzed and reported elsewhere. Fourth, 
although the sample size had adequate power, it was rela-
tively small; future study should therefore attempt to rep-
licate our findings with larger samples. Finally, two inde-
pendent assessors have the same professional license and 
received the same rater training, but lack of interrater re-
liability for LSAS and CGI limits the quality of these as-
sessor-administered outcomes.
 Although this study targeted patients who remain 
symptomatic following antidepressant treatment, we 
need to rethink the first-choice treatment for SAD; ben-
zodiazepine is an alternative first-choice pharmacological 
approach. There has been a progressive shift in prescrib-
ing patterns from benzodiazepine to second-generation 
antidepressants in anxiety disorders  [42] . However, re-
cent systematic reviews have revealed that there is no con-
sistent evidence supporting the advantages of using anti-
depressants over benzodiazepine in treating anxiety dis-
orders, and benzodiazepine showed fewer treatment 
withdrawals and adverse events than antidepressants  [43, 
44] . Further, a recent trial reported the inappropriateness 
of first-line sertraline for 297 patients with SAD due to its 
very low rates of response (32%) and remission (13%), 
which are very unlikely to be better than those of a pla-
cebo  [16] . Based on this evidence, Fava  [8] recently sug-
gested that the utilization of antidepressants in anxiety 
disorders should be reduced unless a comorbid major de-
pression is present, benzodiazepine fails to provide ade-
quate relief, or psychotherapeutic alternatives are not 
available.
 CBT still remains an important first-line treatment 
option for SAD. CBT has a number of advantages over 
pharmacotherapy: larger and longer effects, fewer ad-
verse effects, smaller relapse rates, and greater acceptabil-
ity  [45–47] . Further, patients often prefer psychothera-
peutic intervention (this is better known in the depres-
sion literature)  [48] . Taking these factors into account, 
the National Institute for Health and Care Excellence 
(NICE) recently concluded that individual CBT should 
be offered as the first-choice treatment for SAD  [49] . 
However, patient access to psychotherapy is limited in 
many countries because it is more difficult to increase its 
provision than that of pharmacotherapy. As of 2015, Jap-
anese national health insurance covers only pharmaco-
therapy, but not CBT, for anxiety disorders. The UK and 
Australia have introduced initiatives to increase access, 
provided supervised training, and set minimum compe-
tency standards to ensure a consistent standard of psy-
chotherapy. Worldwide, including Japan, such initiatives 
are rare, and more investment is urgently required to im-
prove patients’ access to CBT.
 In conclusion, our results suggest that in patients with 
SAD who remain symptomatic following treatment with 
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antidepressants, CBT is an effective treatment adjunct to 
UC over 16 weeks in reducing the severity of social anxi-
ety symptoms, depressive symptoms, and functional dis-
ability.
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